News

Osaka University and Chugai Pharmaceutical Co Ltd announced the conclusion of a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai. IFReC was selected for the...

First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line following Glivec®* First genomic analysis and 3-year efficacy/safety update for Tafinlar® + Mekinist® combination in BRAF V600E/K-mutant advanced melanoma,...

Valeant Pharmaceuticals International, Inc. announced that Mr. Joseph Papa, Chairman and Chief Executive Officer, will participate at the UBS Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Monday, May 23, 2016...

Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients...

Mallinckrodt plc a leading global specialty biopharmaceutical company confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant...

Takeda Pharmaceutical Company Limited announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016. Mr. Kehoe will be based in Tokyo and reports directly to Christophe Weber, President &...

Shire plc will present new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 169th Annual Meeting of the American Psychiatric Association (APA) in Atlanta, GA, demonstrating its ongoing commitment to furthering the understanding and...